The compounding industry's most ambitious legal counterattack against the two companies that dominate GLP-1 manufacturing just failed at the first hurdle. On August 3, 2026, US District Judge Micaela Alvarez dismissed Strive Specialties, Inc. v. Eli Lilly & Company, No. 5:26-cv-00155 (W.D. Tex.), granting motions filed by both Eli Lilly and Novo Nordisk. Law360 and MLex reported the order on August 6.
The reasoning is what makes it worth reading rather than the outcome. Strive did not lose because the court found its allegations untrue. It lost because the court held there was no shared market in which the alleged conduct could have suppressed competition — compounded GLP-1 medications and the branded products, in the court's framing, were never competing for the same buyers in the first place.
Research-context information only. This article reports on a published federal court order and contemporaneous legal reporting. Nothing here is medical or legal advice, and nothing here should be read as a prediction of how any appeal or amended complaint would be decided. Semaglutide, tirzepatide and liraglutide are FDA-approved as prescription medicines; the research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity or potency in that channel. Retatrutide is investigational and is not approved for any use in humans in the United States. Consult a licensed physician for personal medical decisions.
What Strive alleged
Strive Compounding Pharmacy, an Arizona-based 503A pharmacy, filed the complaint on January 14, 2026. The theory was a coordinated squeeze on three chokepoints rather than a single act:
Telehealth exclusivity. The complaint alleged that Lilly and Novo Nordisk entered agreements with telehealth platforms that barred those platforms from offering or referring to compounded GLP-1 products. Since the shortage-era boom, telehealth was the dominant acquisition channel for compounded semaglutide and tirzepatide — a patient's route to a compounded prescription usually ran through a platform, not a local pharmacy walk-in. Strive characterised those agreements as cutting off the essential channel between patients holding prescriptions for personalised medicines and the pharmacies that could fill them.
Payment processing. Strive alleged interference with its relationships with payment processors and technology platforms, limiting its ability to accept cash payment for prescriptions. This is the least-discussed allegation and, for anyone watching the wider peptide supply landscape, the most consequential — processor loss rather than regulatory action has been the proximate cause of most vendor exits over the past two years, a pattern documented in our vendor shutdown record.
Characterisation of compounded product. The complaint alleged the manufacturers repeatedly described compounded GLP-1 medications as unsafe, illegal, counterfeit or never safe, notwithstanding that patient-specific compounding is expressly authorised under federal law when prescribed for an individual patient.
The State of Texas filed a motion for leave to submit an amicus brief on July 21, 2026, before the ruling issued.
The holding: no shared market, so no competition to suppress
Antitrust claims of this shape live or die on the relevant market. A plaintiff has to plead a market in which the defendant holds power, and in which the challenged conduct excluded a genuine competitor. Judge Alvarez found Strive had not done that.
The operative passage, as reported: "Because compound GLP-1 medications are only available to patients that cannot use branded GLP-1 medications as a matter of medical necessity, they cannot reasonably be understood as an interchangeable substitute for branded GLP-1 medications in the ordinary sense of market competition."
Read that carefully, because it is doing more work than it appears to. The court took the post-shortage regulatory position — that a 503A pharmacy may compound a copy of a commercially available drug only where a prescriber documents a patient-specific clinical need the commercial product cannot meet — and treated it as an economic fact about the market. If the law only permits compounded product to reach patients who medically cannot take the branded version, then by construction it is not competing for the patients who can. The regulatory narrowing of 2025 and 2026 became the reason the antitrust claim failed in 2026.
Every downstream claim collapsed with the market definition. Exclusive telehealth agreements cannot be exclusionary if the excluded product was never a substitute. The same logic disposes of the processor-interference and disparagement theories at the pleading stage.
The complaint was dismissed in its current form rather than the dispute being resolved finally. Strive has said it is considering an appeal, and an amended complaint pleading a different market — a compounded-only market, or a market defined around patients with a documented clinical need — remains theoretically available. Novo Nordisk shares rose on the news.
What this changes in practice
Nothing about the ruling alters what a pharmacy may legally compound. That question is governed by the 503A and 503B framework, by the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, and by the state pharmacy board overlays that sit on top of the federal floor. Those tracks continue on their own timetable.
What the ruling does change is the outlook for the prescribed compounded route as a cost channel. Three things follow.
The telehealth chokepoint holds. The arrangements Strive attacked survive unchallenged. For the platforms that dominate GLP-1 prescribing, the incentive to route patients to branded product rather than compounded product is now legally undisturbed — and there is no live case threatening it. Our coverage of the June 2026 FDA warning letters to telehealth sellers tracks the enforcement side of the same channel.
Payment processing stays a private lever. The processor allegation drew no separate treatment because the market holding disposed of everything. For readers who follow supply, this is the through-line that connects the pharmacy world to the research-vendor world: neither has a workable legal theory for keeping a processor at the table, and processor loss remains the fastest way a supplier disappears.
The compounded route is now judicially described as a carve-out, not a discount tier. During the 2023-2024 shortage, compounded product functioned as the cheap tier — that was its practical role for most buyers, whatever the legal theory. This opinion writes the opposite into a federal order: compounded GLP-1 exists for the medically excluded, not for the price-sensitive. On the court's own framing, the prescribed compounded route is not a durable low-cost path — it is a narrow accommodation whose availability turns on a documented clinical need rather than on price.
The research-use-only channel is a different thing entirely and was not before the court. Vendors selling on that basis are not pharmacies, do not fill prescriptions, and hold no compounding licence that this order or the 503B docket could reach. That material is also not FDA-approved for human use and has not been evaluated for safety, purity or potency as sold — the distinction our legality guide covers in full. For that channel, current per-milligram pricing, coupon status and COA availability sit on the buying surfaces:
